Download video

V1221 20220819 081553

55 views

gauss002

9 months ago

V1221 20220819 081553

V1221 20220819 081553

Phase I\/II study of a quizartinib, venetoclax, \& decitabine triplet regimen in FLT3-ITD mutated AML
2:11
Phase I\/II study of a quizartinib, venetoclax, \& decitabine triplet regimen in FLT3-ITD mutated AML
by VJHemOnc – Video Journal of Hematology \& HemOnc
Insights into a Phase I\/Ia study of venetoclax, ixazomib and dexamethasone for R\/R AL amyloidosis
1:19
Insights into a Phase I\/Ia study of venetoclax, ixazomib and dexamethasone for R\/R AL amyloidosis
by VJHemOnc – Video Journal of Hematology \& HemOnc
Addition of inotuzumab to alloSCT conditioning regimen in relapsed CD22 (+) lymphoid malignancies
2:19
Addition of inotuzumab to alloSCT conditioning regimen in relapsed CD22 (+) lymphoid malignancies
by VJHemOnc – Video Journal of Hematology \& HemOnc
HELIOS-B Trial of vutrisiran in transthyretin amyloidosis with cardiomyopathy
2:38
HELIOS-B Trial of vutrisiran in transthyretin amyloidosis with cardiomyopathy
by Johnson Francis, MBBS, MD, DM
Menin inhibitors in AML: mechanism of action, the current key data, and predicting efficacy
7:27
Menin inhibitors in AML: mechanism of action, the current key data, and predicting efficacy
by VJHemOnc – Video Journal of Hematology \& HemOnc
All About Ninlaro (Ixazomib) for Multiple Myeloma
11:40
All About Ninlaro (Ixazomib) for Multiple Myeloma
by HealthTree University for Multiple Myeloma
How I give venetoclax + azacitidine to patients with AML
14:27
How I give venetoclax + azacitidine to patients with AML
by Aaron Goodman MD (\\"Papa Heme\\")
Cardiovascular evaluation For multiple myeloma
1:58
Cardiovascular evaluation For multiple myeloma
by MBBS NAIJA
Amyloidosis (amyloid light chain) in multiple myeloma
2:42
Amyloidosis (amyloid light chain) in multiple myeloma
by MBBS NAIJA
Lisaftoclax combinations in R\/R myeloma and AL amyloidosis
2:28
Lisaftoclax combinations in R\/R myeloma and AL amyloidosis
by VJHemOnc – Video Journal of Hematology \& HemOnc
Molecular predictors of response to venetoclax plus azacitidine in R\/R AML
2:35
Molecular predictors of response to venetoclax plus azacitidine in R\/R AML
by VJHemOnc – Video Journal of Hematology \& HemOnc
9D93F609530811B5F6900A229DE0F7#3
0:25
9D93F609530811B5F6900A229DE0F7#3
by River Valley Technologies
Bleximenib combined with venetoclax and azacitidine in R\/R AML with KMT2A or NPM1 alterations
3:09
Bleximenib combined with venetoclax and azacitidine in R\/R AML with KMT2A or NPM1 alterations
by VJHemOnc – Video Journal of Hematology \& HemOnc
Dose-escalation results from Phase Ib\/IIa trial of AZD4573 + acalabrutinib in R\/R DLBCL
3:34
Dose-escalation results from Phase Ib\/IIa trial of AZD4573 + acalabrutinib in R\/R DLBCL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Phase II study of acalabrutinib, venetoclax, and obinutuzumab in CLL enriched for high-risk disease
2:12
Phase II study of acalabrutinib, venetoclax, and obinutuzumab in CLL enriched for high-risk disease
by VJHemOnc – Video Journal of Hematology \& HemOnc
Results of a Phase I study of sonrotoclax for the treatment of R\/R Waldenström’s macroglobulinemia
1:19
Results of a Phase I study of sonrotoclax for the treatment of R\/R Waldenström’s macroglobulinemia
by VJHemOnc – Video Journal of Hematology \& HemOnc
Revumenib plus azacitidine and venetoclax in older adults with NPM1-mutated or KMT2A-rearranged AML
1:25
Revumenib plus azacitidine and venetoclax in older adults with NPM1-mutated or KMT2A-rearranged AML
by VJHemOnc – Video Journal of Hematology \& HemOnc
14.4 Million Years to Go?
37:03
14.4 Million Years to Go?
by Labroots
$13. Large B-cell lymphoma
52:16
$13. Large B-cell lymphoma
by Advanced VnPathoinformatics